Financial reports
ARS
2023 FY
Annual report to shareholders
10 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
12 Apr 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
26 Apr 24
8-K
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
25 Apr 24
8-K
Other Events
8 Apr 24
8-K
Entry into a Material Definitive Agreement
29 Mar 24
8-K
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
29 Mar 24
8-K
Other Events
16 Jan 24
8-K
Vincerx Pharma Reports Third Quarter 2023 Financial Results
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Sep 23
8-K
Vincerx Pharma Reports Second Quarter 2023 Financial Results
7 Aug 23
8-K
Material Modifications to Rights of Security Holders
20 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
25 Apr 24
424B5
Prospectus supplement for primary offering
29 Mar 24
S-8
Registration of securities for employees
28 Mar 23
S-8
Registration of securities for employees
29 Mar 22
424B3
Prospectus supplement
28 Jan 22
S-3
Shelf registration
19 Jan 22
424B3
Prospectus supplement
11 Jan 22
424B3
Prospectus supplement
11 Jan 22
POS AM
Prospectus update (post-effective amendment)
7 Jan 22
POS AM
Prospectus update (post-effective amendment)
7 Jan 22
Proxies
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 23
DEF 14A
Definitive proxy
12 Apr 23
DEFA14A
Additional proxy soliciting materials
12 Apr 22
DEF 14A
Definitive proxy
12 Apr 22
DEF 14A
Definitive proxy
12 Apr 21
DEFM14A
Proxy related to merger
4 Dec 20
PRER14A
Preliminary revised proxy
27 Nov 20
PRER14A
Preliminary revised proxy
10 Nov 20
Other
EFFECT
Notice of effectiveness
31 Jan 22
CORRESP
Correspondence with SEC
26 Jan 22
UPLOAD
Letter from SEC
25 Jan 22
EFFECT
Notice of effectiveness
11 Jan 22
EFFECT
Notice of effectiveness
11 Jan 22
EFFECT
Notice of effectiveness
26 Oct 21
CORRESP
Correspondence with SEC
21 Oct 21
UPLOAD
Letter from SEC
20 Oct 21
EFFECT
Notice of effectiveness
10 Feb 21
CORRESP
Correspondence with SEC
5 Feb 21
Ownership
SC 13G/A
GOLDMAN SACHS GROUP INC
9 Apr 24
4
Raquel E. Izumi
8 Mar 24
4
Alexander A. Seelenberger
8 Mar 24
4
Ahmed MD Hamdy
8 Mar 24
4
TOM C THOMAS
8 Mar 24
SC 13G/A
Long Focus Capital Management, LLC
14 Feb 24
SC 13G
BANK OF AMERICA CORP /DE/
13 Feb 24
SC 13G/A
Affinity Asset Advisors, LLC
13 Feb 24
SC 13G/A
GOLDMAN SACHS GROUP INC
5 Feb 24
4
Alexander A. Seelenberger
14 Aug 23